RESEARCH TRIANGLE PARK, N.C., May 30, 2012-- Stiefel, a GSK GSK +0.11% company, and Welichem Biotech, Inc. (wbi:CN), have entered into an agreement for the acquisition by Stiefel of exclusive ...
GSK Earnings: Strong Start to the Year Driven by Growth in Specialty Medicines GSK posted 6% year-on-year earnings growth at constant currency and core operating profit margin of 32.9%, or 180 basis ...
We are holding firm to our GSK fair value estimate of $54 and our wide moat rating following the Delaware State Court Daubert ruling that allows Zantac plaintiff experts in future litigation. The ...
* GSK SEES SALES GROWTH MORE THAN 5% AND ADJUSTED OPERATING PROFIT GROWTH MORE THAN 10% CAGR 2021-26 * GSK - NEW CONSUMER HEALTHCARE COMPANY SHARES EXPECTED TO ATTAIN A PREMIUM LISTING ON THE LSE, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback